Sunpongsri Supita, Kovitvadhi Attawit, Rattanasrisomporn Jatuporn, Trisaksri Viphavee, Jensirisak Nichakorn, Jaroensong Tassanee
Kasetsart University Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Kasetsart University, 50 Ngamwongwan Rd., Lat Yao, Chatuchak, Bangkok 10900, Thailand.
Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, 50 Ngamwongwan Rd., Lat Yao, Chatuchak, Bangkok 10900, Thailand.
Animals (Basel). 2022 Mar 31;12(7):900. doi: 10.3390/ani12070900.
Feline leukemia virus (FeLV) infection is considered a poor prognostic factor for feline lymphoma. This study investigated the prevalence of cats suffering from feline lymphoma with natural infection of the feline leukemia virus, as well as clinical signs, adverse events, and survival time after cyclophosphamide, vincristine and prednisolone (COP) chemotherapy. This retrospective study involved 92 cats diagnosed with mediastinal or mediastinal plus other anatomical sites of lymphoma and treated with COP chemotherapy. FeLV-antigen-positive was observed in all cats. Clinical signs and adverse events were observed after the 1st, 2nd, and 3rd inductions. Clinical signs improved after the 3rd induction of COP chemotherapy. The response rate was 96.74% (81.52% complete response, 15.22% partial response, and 3.26% no response). The overall median survival time was 338 days (range 62−1057 days). The overall response rate and median survival time of cats with feline lymphoma that were FeLV-antigen-positive and treated with COP chemotherapy were higher than from other studies. This study found that cats aged <4 years survived longer than those aged at least 4 years. Anemia (before COP), azotemia (after 2nd induction), and elevated alanine aminotransferase (after 1st induction) were associated with an increased chance of mortality.
猫白血病病毒(FeLV)感染被认为是猫淋巴瘤预后不良的一个因素。本研究调查了自然感染猫白血病病毒的猫淋巴瘤患猫的患病率,以及环磷酰胺、长春新碱和泼尼松龙(COP)化疗后的临床症状、不良事件和生存时间。这项回顾性研究纳入了92只被诊断为纵隔或纵隔加其他解剖部位淋巴瘤并接受COP化疗的猫。所有猫均检测到FeLV抗原阳性。在第1、2和3次诱导化疗后观察临床症状和不良事件。在第3次诱导COP化疗后临床症状有所改善。缓解率为96.74%(完全缓解率81.52%,部分缓解率15.22%,无缓解率3.26%)。总体中位生存时间为338天(范围62 - 1057天)。FeLV抗原阳性并接受COP化疗的猫淋巴瘤患猫的总体缓解率和中位生存时间高于其他研究。本研究发现,年龄小于4岁的猫比年龄至少4岁的猫存活时间更长。贫血(COP化疗前)、氮质血症(第2次诱导化疗后)和丙氨酸转氨酶升高(第1次诱导化疗后)与死亡几率增加相关。